The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, showcased the most cutting-edge data in the field of hematology by research groups from all over the world. Speaking from the conference, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the most anticipated data to be presented. These include details of the ECHELON-1 trial (NCT01712490), the efficacy of acalabrutinib in relapsed mantle cell lymphoma, follow up data on the LyMa trial (NCT00921414), and an evaluation of current PET scanning practices.
Key abstracts being presented at ASH 2017
